We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Luna Innovations Plans Preclinical Studies and Collaboration with National Cancer Institute

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Luna Innovations Plans Preclinical Studies and Collaboration with National Cancer Institute"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Luna Innovations Incorporated has announces the National Cancer Institute has selected Luna’s magnetic resonance imaging (MRI) contrast agent candidate for preclinical characterization by the Nanotechnology Characterization Laboratory (NCL), a national resource and knowledge base for cancer researchers.

The NCL was established to perform and standardize the preclinical characterization of nanomaterials intended for therapeutics and diagnostics. Luna’s contrast agent for MRI is a modified fullerene compound with the potential to provide a completely new approach to enhancing contrast during MRI procedures.

Luna’s technology may also prevent the toxicity currently associated with gadolinium, a contrast substance frequently used in MRI which has been associated with health problems.

“The core of Luna’s commercialization strategy is to develop technologies in alliances with valued partners, including federal labs, universities, and other businesses. In this collaboration with the NCL, we will be working together to perform preliminary studies, which will further develop our nanotechnology strategy towards application and provide preliminary characterization data. The data can be used to aid the regulatory process and in the transition to commercialization,” said Luna Chairman and CEO, Dr. Kent Murphy.

“We are pleased to have been selected for this program, which can help to accelerate the development of our nanomaterials-based contrast agent and we believe will improve contrast, while using less agent and improving upon safety.”

The U.S. Food and Drug Administration (FDA) and the National Institute of Standards and Technology (NIST) are partners of the NCL with its intent to accelerate the transition of basic nano-biotech research into clinical applications.

A panel consisting of scientists from the NCL, the NCI, the pharmaceutical industry, the NIST, the FDA and the nanotechnology industry evaluate and select proposal applications from a large number of potential nanomaterials candidates. Nanomaterials selected for characterization are based on their projected impact on clinical cancer applications and/or furthering nanotechnology’s compatibility with biological systems.

Studies of Luna’s MRI candidate will include characterization of its physical attributes, its in vitro biological properties and its in vivo compatibility using animal models. Critical parameters related to distribution, metabolism, elimination and toxicity will be examined. The time to characterize a nanomaterial through the NCL, from receipt through the in vivo phase, is anticipated to be one year.